We've learned that KKR now owns LCY Biosciences. De facto KKR owns BioAmber's technology. Being a company whose holding earned $244B last year with a value of $700B, it would seem strange that Mr Eno would sell off all BioAmber's assets for $4.34M. Pretty good catch for KKR. Of course ... there's gotta be a catch. Especially with BioAmber, Inc., again popping up now.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.